Novartis' Afinitor Goes To Panel Review With Trouble Areas For FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
The Oncology Drugs Advisory Committee will review everolimus for certain advanced neuroendocrine tumors on April 12; the pivotal trial used progression-free survival and a crossover design, both areas that FDA has critiqued.
You may also be interested in...
Discordant Trial Results Among Issues FDA Bringing To Advisory Panel Review Of Novartis' Afinitor
The change in endpoints for the two pivotal studies in neuroendocrine tumors and the fact that they don't support each other will fuel the Oncologic Drugs Advisory Committee discussion of the new indication for everolimus.
Discordant Trial Results Among Issues FDA Bringing To Advisory Panel Review Of Novartis' Afinitor
The change in endpoints for the two pivotal studies in neuroendocrine tumors and the fact that they don't support each other will fuel the Oncologic Drugs Advisory Committee discussion of the new indication for everolimus.
Novartis Sales Grow at Double Digits, Helped by Generics, Vaccines
A diversified business allows the Swiss group to report a 14% sales rise for 2010, although pharma sales growth was just half that